BRCA2 and uterine corpus sarcoma: Furthermore, PARP inhibitors showed a similar cytotoxic effect on uterine sarcoma-derived MES-SA cell lines with NAMPT and PTEN deletions, despite the absence of abnormalities in the BRCA2 gene [51].